---
title: "Senti Biosciences to spin off SENTI-202 assets to Celadon-backed NewCo for CVR worth up to $60 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292759038.md"
description: "Senti Biosciences is spinning off its SENTI-202 assets to a Celadon-backed NewCo. The deal involves a Contingent Value Right (CVR) worth up to $60 million, payable via milestones for BLA filing, FDA approval, and sales targets. Senti will retain its Regulator Dial platform, pivoting to controllable genetic medicines while seeking additional financing for early-stage programs."
datetime: "2026-07-15T11:31:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292759038.md)
  - [en](https://longbridge.com/en/news/292759038.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292759038.md)
generator: "portal-rs"
---

# Senti Biosciences to spin off SENTI-202 assets to Celadon-backed NewCo for CVR worth up to $60 million

-   Celadon-controlled NewCo to acquire Senti Biosciences Holdings’ Gene-Circuit pipeline assets, including rights to AML therapy SENTI-202. \* Consideration is a contingent value right distributed to equity holders, offering up to USD 60 million in milestones over seven years. \* Milestones: USD 10 million on BLA filing and acceptance, USD 20 million on FDA approval, USD 30 million at USD 200 million cumulative net sales. \* Senti Biosciences Holdings to retain the Regulator Dial platform, pivoting to controllable genetic medicines and seeking additional financing to fund early-stage programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150730PRIMZONEFULLFEED9762395) on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [SNTI.US](https://longbridge.com/en/quote/SNTI.US.md)

## Related News & Research

- [Senti Biosciences authorizes $2 million senior secured convertible note issuance to NSG BioInnovation Fund](https://longbridge.com/en/news/297827346.md)
- [Senti Biosciences unit issues USD 4 million senior secured convertible notes to Celadon Partners SPV 24](https://longbridge.com/en/news/296532896.md)
- [Taysha Gene Therapies highlights TSHA-102 Rett gene therapy path toward BLA submission in corporate presentation](https://longbridge.com/en/news/297550820.md)
- [uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says](https://longbridge.com/en/news/297819704.md)
- [Kala Bio signs LOI for exclusive US distribution of Virotek ophthalmology genetic tests](https://longbridge.com/en/news/297646733.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**